LENZ Therapeutics Stock (NASDAQ:LENZ)


OwnershipChartTranscripts

Previous Close

$33.40

52W Range

$16.54 - $38.93

50D Avg

$30.61

200D Avg

$28.08

Market Cap

$889.98M

Avg Vol (3M)

$269.12K

Beta

0.41

Div Yield

$7.21

LENZ Company Profile


LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

Mar 22, 2024

Website

LENZ Performance


Latest Earnings Call Transcripts


Q1 25May 09, 25 | 4:30 PM
Q4 24Mar 19, 25 | 4:30 PM
Q3 24Nov 06, 24 | 8:30 AM